We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+14.65%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$262M
AUM Growth
+$34.4M
(+15%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
4.87%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
59
New
5
Increased
15
Reduced
23
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XENT
Intersect ENT, Inc
XENT
|
+$9.35M |
| 2 |
AKRX
Akorn Inc
AKRX
|
+$5.25M |
| 3 |
Halozyme
HALO
|
+$5.24M |
| 4 |
Heron Therapeutics
HRTX
|
+$5.03M |
| 5 |
Omnicell
OMCL
|
+$4.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$4.62M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
+$4.56M |
| 3 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$2.94M |
| 4 |
DOC
PHYSICIANS REALTY TRUST
DOC
|
+$2.9M |
| 5 |
LeMaitre Vascular
LMAT
|
+$2.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.96% |
| 2 | Energy | 2.6% |
| 3 | Communication Services | 1.68% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$1.96B
| $20.9M | 7.99% |
2,653,654
+79,763
| +3% | +$650K |
|
|
AKRX
2
DELISTED
Akorn Inc
AKRX
| $18.7M | 7.13% |
775,591
+241,067
| +45% | +$5.25M |
|
3
AtriCure
ATRC
$1.92B
| $18.3M | 6.99% |
956,458
+17,446
| +2% | +$306K |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $13.6M | 5.18% |
2,096,495
-185,514
| -8% | -$940K |
|
|
XENT
5
DELISTED
Intersect ENT, Inc
XENT
| $11.4M | 4.37% |
+667,504
| New | +$9.35M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $9.72M | 3.71% |
55,791
+18,543
| +50% | +$3.24M |
|
|
OXFD
7
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $9.64M | 3.68% |
622,238
-125,401
| -17% | -$1.79M |
|
|
ENZ
8
DELISTED
Enzo Biochem, Inc.
ENZ
| $9.39M | 3.58% |
1,121,736
+114,379
| +11% | +$806K |
|
9
Harvard Bioscience
HBIO
$27.5M
| $8.33M | 3.18% |
320,449
+46,036
| +17% | +$1.33M |
|
10
HealthStream
HSTM
$819M
| $7.51M | 2.87% |
309,931
+5,631
| +2% | +$131K |
|
|
TLGT
11
DELISTED
Teligent, Inc
TLGT
| $7.42M | 2.83% |
94,938
-831
| -0.9% | -$59.9K |
|
|
LHCG
12
DELISTED
LHC Group LLC
LHCG
| $6.8M | 2.6% |
126,123
-93,869
| -43% | -$4.56M |
|
|
MDCO
13
DELISTED
Medicines Co
MDCO
| $6.69M | 2.55% |
136,739
+9,014
| +7% | +$411K |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $6.64M | 2.54% |
93,465
-679
| -0.7% | -$39.8K |
|
15
Ligand Pharmaceuticals
LGND
$5.76B
| $6.63M | 2.53% |
100,412
+34,384
| +52% | +$2.26M |
|
16
Veracyte
VCYT
$3.7B
| $6.62M | 2.53% |
720,878
+28,668
| +4% | +$235K |
|
|
ENTL
17
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $5.62M | 2.15% |
407,497
+16,208
| +4% | +$260K |
|
|
KTWO
18
DELISTED
K2M Group Holdings, Inc
KTWO
| $5.57M | 2.13% |
271,698
-2,720
| -1% | -$55.8K |
|
|
19
Heron Therapeutics
HRTX
$93.9M
| $5.46M | 2.08% |
+363,689
| New | +$5.03M |
|
|
20
Omnicell
OMCL
$1.61B
| $5.44M | 2.08% |
+133,823
| New | +$4.93M |
|
|
21
Halozyme
HALO
$9.79B
| $5.37M | 2.05% |
+414,611
| New | +$5.24M |
|
|
SPNC
22
DELISTED
Spectranetics Corp
SPNC
| $5.3M | 2.03% |
182,156
-1,571
| -0.9% | -$41.9K |
|
23
Nektar Therapeutics
NKTR
$2.39B
| $5.24M | 2% |
+14,895
| New | +$3.35M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $5.06M | 1.93% |
566,332
-434,029
| -43% | -$4.62M |
|
|
AMED
25
DELISTED
Amedisys
AMED
| $4.73M | 1.81% |
92,549
-24,730
| -21% | -$1.18M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, First Light Asset Management held 59 positions worth $262M, up 15% from $228M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
First Light Asset Management deployed $12.8M of net new capital in Q1 2017, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was Intersect ENT, Inc: 667,504 shares worth $11.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 78% a quarter earlier, followed by Energy and Communication Services.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $4.62M trimmed.
- First Light Asset Management's largest Q1 2017 buy was Intersect ENT, Inc: 667,504 shares worth $11.4M.
- First Light Asset Management added most to Akorn Inc in Q1 2017, an estimated $5.25M increase.
- First Light Asset Management's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $4.62M.
- First Light Asset Management fully exited Aratana Therapeutics, Inc. in Q1 2017, selling an estimated $2.94M.
- First Light Asset Management's ten largest holdings make up 49% of its $262M portfolio in Q1 2017.
- First Light Asset Management opened 5 new positions and closed 6 in Q1 2017.
- First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $262M.
Based on First Light Asset Management's 13F filing for Q1 2017, filed 15 May 2017.